SCHEMBL14294261

SCHEMBL14294261

COc1ccc(-c2ccc(C(C)=O)c(Cl)c2)cc1F

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RAB9A P51151 3/20 0.48
NPC1 O15118 2/20 0.48
MAPT P10636 2/20 0.48
ERN1 O75460 1/20 0.47
LMNA P02545 1/20 0.46
MAPK1 P28482 1/20 0.46
HTT P42858 1/20 0.46
FFAR1 O14842 1/20 0.46
NAAA Q02083 2/20 0.46
HPGD P15428 1/20 0.44
SMN1; SMN2 Q16637 1/20 0.44
HDAC8 Q9BY41 1/20 0.43
CYP17A1 P05093 1/20 0.43
AR P10275 1/20 0.42
MGLL Q99685 1/20 0.42
PTGS2 P35354 2/20 0.42
PDGFRB P09619 1/20 0.42
PDGFRA P16234 1/20 0.42
PDE4A P27815 1/20 0.42
KCNQ3 O43525 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14294262 0.80 ESR1 (0.50) LMNACYP17A1MGLL
SCHEMBL19270951 0.78 MGLL (0.52) ERN1FFAR1CYP17A1MGLLPTGS2
SCHEMBL9149352 0.78 LMNA (0.60) RAB9AMAPTERN1LMNAMAPK1
SCHEMBL21561215 0.78 LMNA (0.60) RAB9AMAPTERN1LMNAMAPK1
SCHEMBL13609519 0.78 MAPK1 (0.53) RAB9ANPC1MAPTMAPK1HTT
SCHEMBL6401188 0.77 MAPK1 (0.49) RAB9AMAPTLMNAMAPK1HTT
SCHEMBL9464193 0.77 CYP17A1 (0.61) RAB9ANPC1MAPTERN1LMNA
SCHEMBL9720067 0.77 PTGS2 (0.56) RAB9ALMNAMAPK1HTTAR
SCHEMBL13602473 0.77 DHODH (0.53) PTGS2
SCHEMBL14270106 0.76 TUBB1 (0.49) RAB9ANPC1MAPTERN1LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080033049-A1 Hydroxy-Biphenyl-Carbaldehyde Oxime Derivatives and Their Use As Estrogenic Agents WYETH (US) 2008-02-07 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080033049-A1 Hydroxy-Biphenyl-Carbaldehyde Oxime Derivatives and Their Use As Estrogenic Agents ESR1, ESR2, ESRRB RAB9A 3208/4885NPC1 4393/4885MAPT 4641/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.